Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company was founded in 1956 and is based in North Billerica, Massachusetts.
LNTH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for LNTH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lantheus Holdings Inc ranked in the 46th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for LNTH, they are:
Lantheus Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 163 -- greater than 98.64% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 11. This value is greater than 82.92% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
USPH, MMSI, PAHC, IART, and AMGN can be thought of as valuation peers to LNTH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for prostate cancer.The application includes a request for Priority Review which, if granted, will shorten...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the Wells Fargo 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Thursday, Septembe
The FDA approves Lantheus's ([[LNTH]] -0.3%) for VIALMIX RFID an activation device for DEFINITY injectable suspension, an intravenous ultrasound enhancing agent.The RFID tag, which is affixed to the vial label, enables controlling the activation rate and time, ensuring reproducible activation of DEFINITY and thus reducing the risks related to operator or medication errors.A U.S. issued patent on the new VIALMIXRFID...
Joining me today is our President and CEO, Mary Anne Heino, and our CFO, Bob Marshall. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties.
Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today reported financial results for its second quarter ended June 30, 2020.